drugset / Trial / NCT06250335

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

NCT06250335

Phase 2 Active not recruiting 4 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelSupportive care

Summary

To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with ICI-refractory melanoma who are receiving the combination of ipilimumab and nivolumab as part of their standard care.

Timeline

Start
2024-03-01
Primary completion
2027-01-23
Completion
2029-01-23

Drugs

EvaluationDrugModalityDoseRoute
Background Ipilimumab Monoclonal antibody Intravenous
Background Nivolumab Monoclonal antibody Intravenous